Literature DB >> 9378968

Costimulatory signals through B7.1/CD28 prevent T cell apoptosis during target cell lysis.

P T Daniel1, A Kroidl, S Cayeux, R Bargou, T Blankenstein, B Dörken.   

Abstract

Expression of B7 on tumor cells can circumvent T cell tolerance and lead to the generation of tumor cell-specific T cell immunity. The effect of B7 expression on the generation of protective antitumor immunity has been attributed primarily to 1) more efficient T cell activation and 2) better generation of tumor-specific killer T cells. We have investigated the role of costimulation through B7.1 and its receptor, the CD28 molecule, in the generation of allogeneic human CTLs against MCF-7 breast cancer cells. In this setting, we describe how activated CTLs undergo activation-induced cell death upon killing the target cell. Instead of proliferation and clonal expansion, the majority of the CTLs underwent apoptotic cell death. CTL apoptosis could be blocked by 50% when binding of the Fas ligand to its receptor, the CD95 (APO-1/Fas) molecule, was prevented. Fas ligand was detected in the activated T cells, but not in MCF-7 or a panel of other breast cancer cell lines. This excludes an active role for MCF-7 during CTL death and indicates that the CTL apoptosis is due to an autocrine production of the Fas ligand by CTLs. Costimulation of CTLs by retrovirally B7.1-transfected MCF-7 drastically reduced the sensitivity of the CTLs to apoptosis during target contact. Thus, in tumor cell vaccination, B7.1 might play a major role in preventing T cell death by altering T cell susceptibility for apoptosis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9378968

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  10 in total

1.  Expression of CD28 and CD38 by CD8+ T lymphocytes in HIV-1 infection correlates with markers of disease severity and changes towards normalization under treatment. The Swiss HIV Cohort Study.

Authors:  P Bürgisser; C Hammann; D Kaufmann; M Battegay; O T Rutschmann
Journal:  Clin Exp Immunol       Date:  1999-03       Impact factor: 4.330

Review 2.  Fas ligand and the fate of antitumour cytotoxic T lymphocytes.

Authors:  Joe O'Connell
Journal:  Immunology       Date:  2002-03       Impact factor: 7.397

3.  Modulation by IL-2 of CD70 and CD27 expression on CD8+ T cells: importance for the therapeutic effectiveness of cell transfer immunotherapy.

Authors:  Jianping Huang; Keith W Kerstann; Mojgan Ahmadzadeh; Yong F Li; Mona El-Gamil; Steven A Rosenberg; Paul F Robbins
Journal:  J Immunol       Date:  2006-06-15       Impact factor: 5.422

4.  Crystallization and preliminary X-ray crystallographic study of the extracellular domain of the 4-1BB ligand, a member of the TNF family.

Authors:  Jung-Sue Byun; Dong-Uk Kim; Byungchan Ahn; Byoung Se Kwon; Hyun-Soo Cho
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2005-12-16

5.  Role of cytokines in promoting immune escape of FasL-expressing human colon cancer cells.

Authors:  Tong Xu; Bao-Cun Sun; Qiang Li; Xi-Shan Hao
Journal:  World J Gastroenterol       Date:  2005-07-07       Impact factor: 5.742

6.  CD3-mediated activation of tumor-reactive lymphocytes from patients with advanced cancer.

Authors:  I Hellstrom; J A Ledbetter; N Scholler; Y Yang; Z Ye; G Goodman; J Pullman; M Hayden-Ledbetter; K E Hellstrom
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-22       Impact factor: 11.205

7.  The regulation of FasL expression during activation-induced cell death (AICD).

Authors:  T Nguyen; J Russell
Journal:  Immunology       Date:  2001-08       Impact factor: 7.397

Review 8.  Prospects for vaccination in prostate cancer.

Authors:  M J Perry; D Hroulda; A G Dalgleish
Journal:  Drugs Aging       Date:  2000-05       Impact factor: 3.923

Review 9.  T cell-tumor cell: a fatal interaction?

Authors:  D B Chappell; N P Restifo
Journal:  Cancer Immunol Immunother       Date:  1998-10       Impact factor: 6.968

10.  Human urinary bladder transitional cell carcinomas acquire the functional Fas ligand during tumor progression.

Authors:  Dominique Chopin; Reza Barei-Moniri; Pascale Maillé; Marie-Aude Le Frère-Belda; Béatrice Muscatelli-Groux; Nicolò Merendino; Laure Lecerf; Antonella Stoppacciaro; Francesca Velotti
Journal:  Am J Pathol       Date:  2003-04       Impact factor: 4.307

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.